Ribose and Sport Performance
The Effect of Ribose on Performance and Recovery in Athletes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Québec, Quebec, Canada, G1V0A6
- Université Laval
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women
- Training volume > 7hrs/week
- VO2 max > 40 and 45 mg/kg/min (for women and men respectively)
- Otherwise healthy individuals
Exclusion Criteria:
- Pregnant or breastfeeding women
- Individuals with endocrine disorders, hypercholesterolemia, cardiovascular diseases, gut diseases, cancer, anemia, hypoglycemia
- Medication for lipids, diabetes, hypertension, inflammation, autoimmune diseases, mood disorders
- Excessive alcohol consumption (more than two drinks by day for men, one for women), smoking, drug use, supplements or natural products consumption during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ribose
After each of the 3km time trial (3 in total), consumption of ribose incorporated in a sports drink.
|
After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
|
|
Placebo Comparator: Placebo
After each of the 3km time trial (3 in total), consumption of placebo incorporated in a sports drink.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in time to complete the third of 3 consecutive 3km time trials on bike
Time Frame: baseline and 1 week
|
baseline and 1 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance on the 3 consecutive 3km time trials on bike
Time Frame: baseline and 1 week
|
Performance measures: peak power (watts/kg), mean power (watts/kg), time to peak power (sec), total work (kJ) and maximum cadence (RPMmax)
|
baseline and 1 week
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue perception after each of the 3 consecutive 3km time trials on bike
Time Frame: baseline and 1 week
|
Post-exercise fatigue perception on visual analog scale (VAS)
|
baseline and 1 week
|
|
Peak Vo2 consumption during each of the 3km time trials on bike
Time Frame: baseline and 1 week
|
baseline and 1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Benoît Lamarche, PhD, Institute on nutraceuticals and functional foods
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2012-048
- INAF-2012-048
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.